A phase I/II Trial of CRISPR-Cas9-mediated PD-1 knockout Epstein-Barr virus cytotoxic lymphocytes (EBV-CTLs) for advanced stage EBV associated malignancies.

作者:Jia, Wei; Jing, Yan; Shu, Su; Jie, Shao; Yang, Zhao; Qiuping, Xu; Yang; Zhengyun, Zou; Xingxu, Huang; Baorui, Liu
来源:Journal of Clinical Oncology, 2018, 36(15_suppl): TPS3118-TPS3118.
DOI:10.1200/jco.2018.36.15_suppl.tps3118